VasCog Virtual 2021

Highlights

PROGRAMME

11:45 - 12:45 - Oral Session I

Breakout Room 1: Biomarkers I -SVD Pathophysiology (Talks 5 min each)

Chairs: Chris Chen (Singapore), Perminder Sachdev (Australia) 

  1. Association of type 2 diabetes, according to the number of risk factors within target range, with structural brain abnormalities, cognitive performance and risk of dementia- April van Gennip (The Netherlands)
  2. Cerebrospinal fluid biomarkers, brain structural and cognitive performances between normotensive and hypertensive controlled, uncontrolled and untreated 70-year-old adults- Atef Badji (USA)
  3. Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration with high plasma SPP1 associated with short patient survival- Sebastian Lewandowski (Sweden)
  4. AIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the prevent-dementia- Audrey Low (UK)
  5. The impact of Alzheimer biomarkers and vascular factors on cognitive decline in memory clinic patients- Veerle van Gils (The Netherlands)
  6. Validation of a novel clinical neurovascular coupling biomarker- Suzanne E. van Dijk (The Netherlands)
  7. Analyzing multimodal MRI at tract-level with neural networks enhances the prediction of cognitive performance in memory clinic patients with small vessel disease- Alberto De Luca (The Netherlands)
  8. Network-based lesion impact score is an independent predictor of post-stroke cognitive impairment- J. Matthijs Biesbroek (The Netherlands)
  9. Relationship between cerebrovascular pathology and resting-state functional connectivity: a systematic review- Natasha Clarke (Canada)

Breakout Room 2: Stroke, Cognition and Pathophysiology (Talks 5 min each)

Chairs: Ingmar Skoog (Sweden), Louise Allan (Exeter) 

  1. Trajectories of cognitive change following stroke: a stepwise decline towards dementia- Joao Delgado (UK)
  2. Long-Term Outcomes Among Nigerian Stroke Survivors - the CogFAST-Nigeria Study- Gabriel Ogunde (Nigeria)
  3. Brain regions involved in the strategic processes of verbal fluency: a mVLSM study in 337 stroke patients- Flore Dorchies (France)
  4. Patterns and predictors of short-term trajectory of post-stroke cognitive function- Jess Lo (Australia)
  5. Visuospatial dysfunction in Vascular Cognitive impairment subtypes- A comparative study from a tertiary care center in Kolkata- Ashwani Bhat (India)
  6. Pure vascular-ischemic disease and cognitive impairment - Elisabet Englund (Sweden)
  7. Association between Cerebral Small Vessel Disease and Alzheimer’s disease pathologies- Yuan Cai (China)
  8. Combined associations of cognitive and motor impairments with functional outcome in covert cerebral small vessel disease- Hanna Jokinen (Finland)
  9. Cerebral small vessel function in patients with CADASIL and sporadic cerebral small vessel disease: assessment of hemodynamic response function with 7T MRI– the Zoom@svds study, Hilde van den Brink (The Netherlands)

12:50 - 13:00 - Welcome/ Opening (10 min)

Convenors: Raj Kalaria, John O’Brien, Hugh Markus (UK)


13:00 - 13:30 - Plenary I

Clinical VCI: J Wardlaw (UK) 20 min with 10 min discussion

Chair: John O/Brien (UK)


13:30 - 14:45 - Symposium I

The importance of VRF and Heart Variability for Cognition and Dementia: 

Chairs: K Ikram and D Bos (The Netherlands)

  • Orthostatic hypotension/heart failure and dementia - Frank Wolters (The Netherlands) (12 min)
  • Heart rate variability/blood pressure variability and cognition/dementia -Yuan Ma (USA) (12 min)
  • Cardiac dysfunction and cognition/dementia - Saima Hilal (Singapore) (12 min)
  • Cardiac biomarkers: current state-of-the-art - Thomas Vanassche (Belgium) (12 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. Visit-to-Visit Variability in Blood Pressure over 10 Years, Cognitive Decline and Incident Dementia in Three Community-Based Cohorts of Older Adults- Simin Mahinrad (USA)
  2. Investigating the risk of cardiovascular risk factor subgroups in cognitively normal elderly on Alzheimer’s disease: a latent class approach- Myuri Ruthirakuhan (Canada)

Discussion


14:30 - 15:30 - E-poster Blitz session I

Chair:  Adrian Wong (Hong Kong)

  1. Prevalence of cognitive impairment and dementia in  a multi-ethnic elderly cohort the Singapore Epidemiology of Eye Diseases study (SEED)- Ting Pang (Singapore)
  2. Discriminant Validity of the Progressive Forgetfulness Question in a Stepwise Dementia Screening Approach in a Singaporean Elderly Population- Ting Pang (Singapore)
  3. Neurofilament light level correlates with brain atrophy and cognitive and motor performance in subjects with cerebral white matter hyperintensities- Marge Kartau (Finland)
  4. Age-associated changes in the renin-angiotensin system: implications for future clinical trials- Robert MacLachlan (UK)
  5. Renin-angiotensin system gene expression and dementia pathology in Alzheimer’s disease, vascular and mixed dementia- Hannah Tayler (UK)
  6. Angiotensinogen, ACE-1 and ACE-2 in Alzheimer’s disease and vascular dementia- Özge Güzel (UK)
  7. Fibrinogen activates microglia and drives extracellular vesicle mediated propagation of pro-inflammatory signaling- Austyn Roseborough (Canada)
  8. Relationships between Myeloperoxidase and the Cognitive and Neuroimaging Correlates of Mild Vascular Cognitive Impairment- Kritleen Bawa (Canada)
  9. Modelling Alzheimer’s Disease through Environmentally Induced Neurovascular Dysfunction within an In Vitro Cell Model- Ernesto Zarate-Aldrete (UK)
  10. Endothelin-1-mediated contraction of human brain pericytes is dysregulated in the presence of Aβ1-40- Elliott Hibbs (UK)
  11. Automatic quantification of perivascular spaces in T2-weighted images at 7T MRI- Hugo Kuijf (The Netherlands)
  12. Connection Between Kidney Function and Cognition in the Elderly- Tomas Månsson (Sweden)
  13. Low carotid end diastolic velocity is associated with white matter hyperintensities and cortical atrophy in the Swedish "Good Aging in Skane" study- Katarina Ellström (Sweden)
  14. Association of cerebral small vessel disease burden with brain structure and cognitive and vascular risk trajectories in mid-to-late life- Michelle G. Jansen (The Netherlands)
  15. Self-reported cognitive decline, emotional symptoms, and daytime sleep after ischemic stroke- Elisabeth Kliem (Norway)
  16. Social Cognition is Associated with General Cognitive Function Post-Stroke- Elise Gjestad (Norway)
  17. Prevalence of, and risk factors for, vascular cognitive impairment in CADASIL- Amy A Jolly (UK)

 15:30 - 16:00 - Break


16:00 - 17:00 - Symposium II 

Is Brain Inflammation relevant for VCI?

Chairs: Frank Eric de Leeuw (Netherlands) John O’Brien (UK)

  • PET studies of microglial activation and blood brain barrier dysfunction in SVD - Hugh Markus (UK) (15 min)
  • Reprogramming of the peripheral immune system in SVD - Niels Riksen (The Netherlands) (15 min)

2 x ECR talks (open abstracts, 5 mins each)

  1. A cluster of blood-based biomarkers reflecting extracellular matrix organization, inflammation and signal transduction relates to cerebral blood flow in patients with cardiovascular disease - L Malin Overmars (The Netherlands)
  2. Does 11C-PK11195 binding predict lesion growth at one year?- Daniel Tozer (UK)

Discussion


17:00 - 17:30 - Plenary II

Brain vascular extracellular matrix and VCIG Rosenberg (USA) - 20 min with 10 min discussion

Chair:  Eric Smith (Canada)


17:30 - End of Day 1

 
 

BREAKOUT SESSIONS

DAY1: ROOM 1

Biomarkers I -SVD Pathophysiology

DAY1: ROOM 2

Stroke, Cognition and Pathophysiology

DAY2: ROOM 1

Biomarkers II - White Matter Pathophysiology, Vascular Reactivity

DAY2: ROOM 2

Blood Brain Barrier Pathophysiology, Models and Dementias

VIDEO HIGHLIGHTS

Day1: Plenary I
Clinical VCI

Day 1: Symposium I
The importance of VRF and Heart Variability for Cognition and Dementia

Day1: E-poster Blitz session I

Day 1: Symposium II
Is Brain Inflammation relevant for VCI?

 Day 1: Plenary II
Brain vascular extracellular matrix and VCI

 Day 2: Plenary III
Genetics of Stroke and VCI- from discovery to clinical applications

Day 2: Symposium III
Cardiovascular risk management throughout the life course to prevent/treat dementia

 Day 2: Viewpoint session
Aducanumabfor Alzheimer’s Disease

 Day 2: Plenary IV
Risk Factors for SVD: an Asian Perspective

Day 2: E-poster Blitz session II

 Day 2: Plenary V
Gait as a biomarker for VCI

 Day 2: Early Career Researchers (ECR) Session
he future of VCI research: a collaborative approach

Day 2: Plenary VI

Variation in global stroke burden and influence on clinical and brain VCI phenotypes: Implications for prevention

 Day 2: Concluding comments
VasCog Society & VasCog 2023

VIRTUAL POSTERS

Sponsored and supported by: